Translational Toxicology And Therapeutics
DOWNLOAD
Download Translational Toxicology And Therapeutics PDF/ePub or read online books in Mobi eBooks. Click Download or Read Online button to get Translational Toxicology And Therapeutics book now. This website allows unlimited access to, at the time of writing, more than 1.5 million titles, including hundreds of thousands of titles in various foreign languages. If the content not found or just blank you must refresh this page
Translational Toxicology And Therapeutics
DOWNLOAD
Author : Michael D. Waters
language : en
Publisher: John Wiley & Sons
Release Date : 2018-01-04
Translational Toxicology And Therapeutics written by Michael D. Waters and has been published by John Wiley & Sons this book supported file pdf, txt, epub, kindle and other format this book has been release on 2018-01-04 with Medical categories.
Written by leading research scientists, this book integrates current knowledge of toxicology and human health through coverage of environmental toxicants, genetic / epigenetic mechanisms, and carcinogenicity. Provides information on lifestyle choices that can reduce cancer risk Offers a systematic approach to identify mutagenic, developmental and reproductive toxicants Helps readers develop new animal models and tests to assess toxic impacts of mutation and cancer on human health Explains specific cellular and molecular targets of known toxicants operating through genetic and epigenetic mechanisms
Translational Toxicology
DOWNLOAD
Author : Claude L. Hughes
language : en
Publisher: Humana Press
Release Date : 2016-03-23
Translational Toxicology written by Claude L. Hughes and has been published by Humana Press this book supported file pdf, txt, epub, kindle and other format this book has been release on 2016-03-23 with Medical categories.
Bringing together a distinguished interdisciplinary team of contributors, this volume provides a comprehensive exploration of translational toxicology—a systematic approach to developing therapeutic interventions that can protect against, mitigate, or reverse the effects of exposures. In particular, the book addresses modes of action and biomarkers, developmental risks of exposures, and potential translational toxicology therapeutics. The result is a compelling application of developmental toxicology in a new therapeutic discipline that is destined to become part of standard medical practice. Translational Toxicology: Defining a New Therapeutic Discipline is an essential text for regulatory authorities, scientists, and physicians who are concerned with environmental exposures, public health, nutrition, and pharmaceutical research and development. Basic science, epidemiological, and clinical investigators will also find this book a significant resource.
The Coronavirus Pandemic And The Future Virology Epidemiology Translational Toxicology And Therapeutics Volume 1
DOWNLOAD
Author : Michael D. Waters
language : en
Publisher: Royal Society of Chemistry
Release Date : 2022-04-27
The Coronavirus Pandemic And The Future Virology Epidemiology Translational Toxicology And Therapeutics Volume 1 written by Michael D. Waters and has been published by Royal Society of Chemistry this book supported file pdf, txt, epub, kindle and other format this book has been release on 2022-04-27 with Medical categories.
By addressing considerations of efficacy and safety of drugs and chemicals used to combat COVID-19, virtually in real-time, this book documents and highlights the advances in science and place the toxicology, pharmaceutical science, public health and medical community in a better position to advise in future epidemics.
The Coronavirus Pandemic And The Future Virology Epidemiology Translational Toxicology And Therapeutics Volume 2
DOWNLOAD
Author : Claude L. Hughes
language : en
Publisher: Royal Society of Chemistry
Release Date : 2022-04-27
The Coronavirus Pandemic And The Future Virology Epidemiology Translational Toxicology And Therapeutics Volume 2 written by Claude L. Hughes and has been published by Royal Society of Chemistry this book supported file pdf, txt, epub, kindle and other format this book has been release on 2022-04-27 with Medical categories.
This second volume chronicles the later stages of the outbreak of SARS-Cov-2 (COVID-19) and delineates the role of several disciplines in therapeutic and control measures highliting the response from specific coutries of note and efforts to repurpose and produce new therapeutics and vaccines. By addressing considerations of efficacy and safety of drugs and chemicals used to combat COVID-19, virtually in real-time, this book documents and highlights the advances in science and place the toxicology, pharmaceutical science, public health and medical community in a better position to advise in future epidemics.
Translational Medicine
DOWNLOAD
Author : Joy A. Cavagnaro
language : en
Publisher: CRC Press
Release Date : 2021-11-26
Translational Medicine written by Joy A. Cavagnaro and has been published by CRC Press this book supported file pdf, txt, epub, kindle and other format this book has been release on 2021-11-26 with Medical categories.
Translational Medicine: Optimizing Preclinical Safety Evaluation of Biopharmaceuticals provides scientists responsible for the translation of novel biopharmaceuticals into clinical trials with a better understanding of how to navigate the obstacles that keep innovative medical research discoveries from becoming new therapies or even making it to clinical trials. The book includes sections on protein-based therapeutics, modified proteins, oligonucleotide-based therapies, monoclonal antibodies, antibody–drug conjugates, gene and cell-based therapies, gene-modified cell-based therapies, combination products, and therapeutic vaccines. Best practices are defined for efficient discovery research to facilitate a science-based, efficient, and predictive preclinical development program to ensure clinical efficacy and safety. Key Features: Defines best practices for leveraging of discovery research to facilitate a development program Includes general principles, animal models, biomarkers, preclinical toxicology testing paradigms, and practical applications Discusses rare diseases Discusses "What-Why-When-How" highlighting different considerations based upon product attributes. Includes special considerations for rare diseases About the Editors Joy A. Cavagnaro is an internationally recognized expert in preclinical development and regulatory strategy with an emphasis on genetic medicines.. Her 40-year career spans academia, government (FDA), and the CRO and biotech industries. She was awarded the 2019 Arnold J Lehman Award from the Society of Toxicology for introducing the concept of science-based, case-by-case approach to preclinical safety evaluation, which became the foundation of ICH S6. She currently serves on scientific advisory boards for advocacy groups and companies and consults and lectures in the area of preclinical development of novel therapies. Mary Ellen Cosenza is a regulatory toxicology consultant with over 30 years of senior leadership experience in the biopharmaceutical industry in the U.S., Europe, and emerging markets. She has held leadership position in both the American College of Toxicology (ACT) and the International Union of Toxicology (IUTOX) and is also an adjunct assistant professor at the University of Southern California where she teaches graduate-level courses in toxicology and regulation of biologics.
Drug Discovery Toxicology
DOWNLOAD
Author : Yvonne Will
language : en
Publisher: John Wiley & Sons
Release Date : 2016-03-22
Drug Discovery Toxicology written by Yvonne Will and has been published by John Wiley & Sons this book supported file pdf, txt, epub, kindle and other format this book has been release on 2016-03-22 with Medical categories.
As a guide for pharmaceutical professionals to the issues and practices of drug discovery toxicology, this book integrates and reviews the strategy and application of tools and methods at each step of the drug discovery process. • Guides researchers as to what drug safety experiments are both practical and useful • Covers a variety of key topics – safety lead optimization, in vitro-in vivo translation, organ toxicology, ADME, animal models, biomarkers, and –omics tools • Describes what experiments are possible and useful and offers a view into the future, indicating key areas to watch for new predictive methods • Features contributions from firsthand industry experience, giving readers insight into the strategy and execution of predictive toxicology practices
Development Of Antibody Based Therapeutics
DOWNLOAD
Author : Mohammad A. Tabrizi
language : en
Publisher: Springer Science & Business Media
Release Date : 2012-04-24
Development Of Antibody Based Therapeutics written by Mohammad A. Tabrizi and has been published by Springer Science & Business Media this book supported file pdf, txt, epub, kindle and other format this book has been release on 2012-04-24 with Medical categories.
Translational strategies for development of antibody-based therapeutics should allow understanding of the relationship between the ‘unit dose’ and ‘unit effect’ with respect to both beneficial and deleterious effects from early stages of development. The flow of information from later to earlier stages of development should provide opportunities to facilitate selection of more effective novel and next-generation drug candidates. Selection and evaluation of relevant biomarkers in early preclinical development in "relevant" animal models should allow for identifying potential risks to humans and establishing safe First-In-Human (FIH) dosing strategies. Hence, integration of knowledge with respect to target antigen properties such as antigen distribution, expression profile, kinetic properties, target pharmacology, antigen isoforms and pharmacological redundancy in health and disease, as well as antibody design criteria, such as antibody isotype, affinity, PK/PD and safety is a critical necessity for the design of effective translational strategies. Additionally, these factors will further offer critical differentiating characteristics for next-generation antibodies, and novel technologies prove instrumental in generation of biosuperior antibody candidates for market entry. This book will examine many important considerations necessary for the design of effective translational strategies during the development of antibody-based therapeutics.
Human Based Systems For Translational Research
DOWNLOAD
Author : Robert Coleman
language : en
Publisher: Royal Society of Chemistry
Release Date : 2014-12-08
Human Based Systems For Translational Research written by Robert Coleman and has been published by Royal Society of Chemistry this book supported file pdf, txt, epub, kindle and other format this book has been release on 2014-12-08 with Science categories.
This book provides a history and discussion of the use of human tissues as an alternative to animal-based testing for assessing the efficacy and safety of new medicines. Beginning by providing a historical background to animal-based testing, this text then describes in detail the issues relating to access to human cells and tissue and the rules and regulations governing their use. The book illustrates what is currently possible in humanising medicines research and development, and suggests more rational and reliable means of developing safe and effective drugs for the future than those on which we currently rely. Early chapters establish the need to generate more data in human-derived test systems, and the need for resources such as tissue banks and standardised processes whilst highlighting the barriers that have prevented such developments so far. Subsequent chapters explore the alternatives to current animal toxicology studies, including stem cells and computational models, with balanced views of the technical challenges and opportunities these offer. In addition, useful information on computational methods and pharmacokinetics are included. This book is an essential read for anyone engaged in translational drug discovery who wishes to consolidate their understanding and broaden their awareness of the key issues involved in accessing primary human tissue and the advantages of doing so.
Development Of Antibody Based Therapeutics
DOWNLOAD
Author :
language : en
Publisher: Springer
Release Date : 2012-04-25
Development Of Antibody Based Therapeutics written by and has been published by Springer this book supported file pdf, txt, epub, kindle and other format this book has been release on 2012-04-25 with categories.
Development Of Antibody Based Therapeutics
DOWNLOAD
Author : Mohammad A. Tabrizi
language : en
Publisher:
Release Date : 2018
Development Of Antibody Based Therapeutics written by Mohammad A. Tabrizi and has been published by this book supported file pdf, txt, epub, kindle and other format this book has been release on 2018 with Biochemistry categories.
With a key focus on recent developments and advances in the field, this book provides in-depth coverage of topics fundamental to the development of targeted therapeutics. The expansion of targeted modalities in rapidly evolving therapeutic areas, such as immune-oncology, and developments with respect to combination therapies, novel technologies, and the therapeutic application of antibody-drug conjugates, are presented. Additionally, the book builds upon topics discussed in the first edition (2012) where recent innovations warrant elaboration. This, the second edition of Development of Antibody-Based Therapeutics: Translational Considerations, represents a comprehensive evaluation of progress in the field, which sits alongside the first edition to inform, in detail, professional and academic researchers, as well as graduate students. Mohammad A. Tabrizi, Ph. D. is a leader in translational sciences as related to development of antibody-based therapeutics.^His product development experience spans many therapeutic areas including oncology and inflammatory disease, and his technical expertise includes preclinical pharmacology and safety, preclinical and clinical pharmacokinetics, pharmacodynamics, GLP-compliant bioanalytics, and clinical pharmacology of therapeutic monoclonal antibodies. Gadi Bornstein, Ph. D. has over seventeen years of experience in Oncology R & D with an emphasis in preclinical antibody discovery and development. Dr. Bornstein currently leads and directs biologics discovery efforts at TESARO. He received his B.S. in biochemistry at the University of California, Davis and his doctoral degree in biochemistry at the University of Southern California Keck School of Medicine. Dr. Bornstein completed his postdoctoral training at Stanford University in the Division of Immunology and Rheumatology. Following his postdoctoral training, Dr. Bornstein joined Amgen Fremont, Inc.^(formerly Abgenix, Inc.) as a Staff Scientist in the Preclinical Oncology department. Dr. Bornstein has held roles of increasing responsibility at AstraZeneca, Pfizer, and Novartis, where he was a project team leader, lead biologist, and key contributor to scientific strategies for multiple oncology programs. Dr. Bornstein has authored numerous research papers, reviews, as well as book chapters, and is a co-inventor on multiple patents. Scott L. Klakamp, Ph. D. is one of the leading scientists in utilizing Surface Plasmon Resonance (SPR) and KinExA® to measure the binding kinetics and equilibrium dissociation constants of human monoclonal antibody/antigen complexes. He was the founder of SKD Consulting LLC and acted as Principal Consultant at that company during the development of this title. Prior to SKD Consulting LLC, he was the Vice President of Chemistry and Biochemistry at BiOptix Inc., a company that provided the 404pi biosensor. Dr.^Klakamp has also held positions of increasing responsibility in the areas of analytical and biophysical characterization at Chiron, Amgen/Abgenix, AstraZeneca/MedImmune, and Takeda Pharmaceuticals. Dr. Klakamp has been an author on over 30 research and review papers, book chapters, and patents. He has also been an invited speaker at numerous international and national meetings. Dr. Klakamp received his B.A. in Chemistry from Houghton College and his PhD in Chemistry at the Pennsylvania State University. From 1990 to 1993, he completed a postdoctoral fellowship (funded by a National Research Service Award from the National Institutes of Health) at the California Institute of Technology in bioinorganic chemistry.